COMMUNIQUÉS West-GlobeNewswire

Progyny, Inc. Executives to Participate in Upcoming Investor Conferences
06/03/2026
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that several members of its leadership team will participate in [...]
Transforming Healthcare Ltd Founder Dr. Pietro Emanuele Garbelli Wins BREW Readers' Book of the Month for 'The Doctor's Future'
06/03/2026
Transforming Healthcare Ltd founder recognised by BREW and profiled by The World’s Best on accountable AI, robotics, and the future of medicine London, GREATER LONDON, March 06, 2026 (GLOBE NEWSWIRE) -- London, UK — 6 [...]
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
06/03/2026
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical [...]
Holland Bloorview Kids Rehabilitation Hospital launches its 10th annual Capes for Kids fundraiser
06/03/2026
Calling all fundraisers to don their capes from March 6-13 to support children with disabilities Toronto, March 06, 2026 (GLOBE NEWSWIRE) -- Holland Bloorview Kids Rehabilitation Hospital (Holland Bloorview) kicks off [...]
SleepZee Anti-Snoring Mouthpiece Consumer Report: 2026 Analysis of Mandibular Advancement Device Research, Snoring Reduction Claims, and What Buyers Should Verify
06/03/2026
A 2026 informational consumer research report examining SleepZee anti-snoring mouthpiece mandibular advancement claims, boil-and-bite snoring mouth guard effectiveness research, company Terms of Service disclosures, [...]
Nika Pharmaceuticals, Inc. (NIKA) Signed a Consultancy Agreement with MD Global Partners LLC
06/03/2026
HENDERSON, Nev., March 06, 2026 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) announces that it has signed a consultancy agreement with MD Global Partners LLC, a leading Manhattan-based investment bank. [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
06/03/2026
Nantes, le 6 mars 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée de [...]
EssilorLuxottica: Mise à disposition du Document d’enregistrement universel 2025
06/03/2026
Mise à disposition du Document d’enregistrement universel 2025 Paris, France (6 mars 2026) – EssilorLuxottica annonce la mise à disposition de son Document d’enregistrement universel 2025 dans les conditions requises [...]
EssilorLuxottica: 2025 Universal Registration Document filed
06/03/2026
2025 Universal Registration Document filed Paris, France (6 March 2026) – EssilorLuxottica announces the availability of its 2025 Universal Registration Document, in accordance with applicable regulation. The French [...]
VALNEVA Déclaration d’actions et de droits de vote : 28 février 2026
06/03/2026
VALNEVA Déclaration d’actions et de droits de vote 28 février 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : Îlot [...]
VALNEVA Declaration of shares and voting rights: February 28, 2026
06/03/2026
VALNEVA Declaration of shares and voting rights February 28, 2026 __________________________________________________________________________________________ Company name: VALNEVA Registered office: Îlot Saint-Joseph [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
06/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 6 March 2026 at 16.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
06/03/2026
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms Gazyva/Gazyvaro has the potential to [...]
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
06/03/2026
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that [...]
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
06/03/2026
Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a [...]
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
06/03/2026
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total equity value of [...]
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
06/03/2026
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced [...]
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
06/03/2026
Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹ Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as well as all other [...]

Pages